Glenmark Pharmaceuticals Limited (GLENMARK) Stock Statistics & Valuation Metrics

Glenmark Pharmaceuticals Limited has a market cap or net worth of ₹627.35B. The enterprise value is ₹636.18B.

Glenmark Pharmaceuticals Limited has 282,200,800 shares outstanding. The number of shares has decreased by -2.65% in one year.

Glenmark Pharmaceuticals Limited’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 11.77%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Glenmark Pharmaceuticals Limited had revenue of 131.46B and earned 10.47B in profits. Earnings per share was 37.11.

In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.

Glenmark Pharmaceuticals Limited pays an annual dividend of ₹2.5, resulting in a dividend yield of 0.11%

Glenmark Pharmaceuticals Limited upcoming earnings date is Aug 8, 2025, During Market Hours (Confirmed).

Glenmark Pharmaceuticals Limited as a current ratio of 1.56, with Debt / Equity ratio of 27.94%

In the past 12 months, Glenmark Pharmaceuticals Limited has paid 3.52B in taxes.

Glenmark Pharmaceuticals Limited EV to EBITDA ratio is 20.73, with an EV/FCF ratio of -27.51.

Glenmark Pharmaceuticals Limited has ₹17.68B in cash and marketable securities with ₹24.73B in debt, giving a net cash position of ₹7.05B billion.

Gross margin is 54.38%, with operating margin of 14.19%, and net profit margin of 7.97%.

The average price target for Glenmark Pharmaceuticals Limited is ₹1,857.50, which is 11.43% higher than the current price. The consensus rating is Hold